Get started
Author

Ellen nong Wei

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
2004 · Suzanne Trudel, Zhi Hua Li, et al. · Blood · 289
PDF
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
2006 · Suzanne Trudel, A. Keith Stewart, et al. · Blood · 142
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
2010 · Christine I. Chen, P. Leif Bergsagel, et al. · Journal of Clinical Oncology · 139
PDF
MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
2006 · Esther Masih-Khan, Suzanne Trudel, et al. · Blood · 80
The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades
2004 · Yuan Xiao Zhu, Sally Benn, et al. · The Journal of Experimental Medicine · 60
A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL).
2007 · Christine I. Chen, Harminder Paul, et al. · Blood · 35
Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression
2021 · Danielle C. Croucher, Laura M. Richards, et al. · Nature Communications · 29
PDF
Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium
2016 · Suzanne Trudel, Nizar J. Bahlis, et al. · Blood · 20
Long‐term follow‐up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia
2014 · Christine I. Chen, Harminder Paul, et al. · British Journal of Haematology · 19
PDF
Murine phosphatidylserine-specific phospholipase A1 (Ps-pla1) maps to Chromosome 16 but is distinct from the lpd (lipid defect) locus
2001 · Xiao-Yan Wen, A. Keith Stewart, et al. · Mammalian Genome · 13
A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*
2018 · Christine I. Chen, Harminder Paul, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 10
A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
2008 · Christine Chen, Harminder Paul, et al. · Blood · 10
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)
2018 · Christine I. Chen, Harminder Paul, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 9
Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134
2011 · Sheng-Ben Liang, Xiu-Zhi Yang, et al. · Clinical Cancer Research · 9
Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
2012 · Christine Chen, Harminder Paul, et al. · Blood · 6
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
2025 · Tess Aalto, Maria Abacan, et al. · Cancer Cell · 5
An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).
2012 · Christine Chen, Harminder Paul, et al. · Blood · 5
Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma
2023 · Dor D. Abelman, Jenna Eagles, et al. · Blood · 3
An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
2015 · Christine I Chen, Harminder Paul, et al. · Blood · 3
GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL
2012 · Suzanne Trudel, Sam Scanga, et al. · Blood · 3
Macrophage Inflammatory Protein (MIP)-1alpha (CCL3) Is a Downstream Target of FGFR3 and RAS Signaling in Multiple Myeloma.
2005 · Esther Masih-Khan, Suzanne Trudel, et al. · Blood · 2
Targeting FGFR3 in t(4;14) Mutiple Myeloma: Pre-Clinical Studies of PRO-001, a Novel Anti-FGFR3 Neutralizing Antibody.
2004 · Suzanne Trudel, Ellen Wei, et al. · Blood · 2
Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple Myeloma
2025 · Dor D. Abelman, Jenna Eagles, et al. · medRxiv · 1
Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma
2025 · Liam Hendrikse, Michael St. Paul, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
2015 · Christine I Chen, Susi Snitzler, et al. · Blood · 1
Works count: 48
Citation count: 901
H-index: 10
I10-index: 12
Year
Topic
Type